Хронический гломерулонефрит: аргументы в пользу применения циклоспорина


Л.В. Козловская

Кафедра терапии и профболезней МПФ ММА им. И.М. Сеченова, Москва
Обсуждаются показания к применению циклоспорина для лечения хронического гломерулонефрита. Представлено обоснование его эффективности при нефропатии минимальных изменений, фокально-сегментарном гломеруло-склерозе, мембранозной нефропатии и волчаночном нефрите.

Литература


1. Baran D., Vendeville B., Vial M.C. et al. Effect of cyclosporine A on mercuryinduced autoimmune glomerulonephritis in the Brown Norway rat. Clin.Nephrol. 1986; 25 (Suppl 1): S175–S180.


2. Thaiss F., Mihatsch M.J., Batsford S. et al. Effect of cyclosporine on in situ immune complex glomerulonephritis. Clin. Nephrol. 1986; 25 (Suppl 1): S181–S185.


3. Gunn H.C., Ryffel B. Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine. Clin. Nephrol. 1986;25 (Suppl 1): S189–S192.


4. Waldo F.B., Kohaut E.C. Therapy of focal segmental glomerulosclerosis with cyclosporine A. Pediatr. Nephrol. 1987; 1(2): 180–182.


5. Meyrier A., Simon P. Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis. Adv. Nephrol. Necker Hosp. 1988; 17: 127–150.


6. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol. Dial. Transplant. 2003; 18(Suppl. 6): vi79–vi86.


7. Matsumoto H., Nakao T., Okada T. et al. Initial remission-inducing effect of very low-dose cyclosporine monotherapy for minimal-change nephritic syndrome in Japanese adults. Clin. Nephrol. 2001; 55: 143–148.


8. Matsumoto H., Nakao T., Okada T. et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern. Med. 2004; 43(8): 668–673.


9. Eguchi A., Takei T., Yoshida T. et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephritic syndrome. Nephrol. Dial. Transplant. 2010; 25(1): 124–129.


10. Filler G. How should microemulsified cyclosporine A (Neoral) therapy in nephritic syndrome be monitored? Nephrol. Dial. Transplant. 2005; 20:1032–1034.


11. Ittel T.H., Clasen W., Fuhs M. et al. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin. Nephrol. 1995; 44(3): 156–162.


12. Sheashaa H., Mahmoud I., El-Basuony F. et al. Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? Along-term efficacy and safety study. Int. Urol. Nephrol. 2007; 39(3): 923–928.


13. Plank C., Kalb V., Hinkes B. et al.; Arbeitsgemeinschaft fur Padiatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr. Nephrol.2008; 23(9): 1483–1493.


14. Hamasaki Y., Yoshikawa N., Hattori S. et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2009; 24(11): 2177–2185.


15. Frassinetti Castelo Branco Camurca Fernandes P., Bezerra Da Silva G. Jr., De Sousa Barros F.A. et al. Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17 cases and a literature review. J. Nephrol. 2005;18(6): 711–720.


16. Rasche F.M., Keller F., Kunze G. et al. Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome. Clin. Nephrol. 2007; 67(5): 285–292.


17. Мухин Н.А., Тареева И.Е., Краснова Т.Н., Шилов Е.М., Мирошниченко Н.Г. Лечение нефротической формы хронического гломерулонефрита сандиммуном (циклоспорином А). Тер арх. 1995; 67(8): 13–15.


18. Краснова Т.Н., Тареева И.Е., Шилов Е.М., Мухин Н.А., Мирошниченко Н.Г. Сандиммун в лечении хронического гломерулонефрита с нефротическим синдромом. Терарх. 1995; 69(6): 21–23.


19. Hodson E.M., Willis N.S., Craig J.C. Non-corticosteroid treatment for nephritic syndrome in children. Cochrane Database Syst. Rev. 2008; (1):CD002290


20. Сameron J.S. Focal segmental glomerulosclerosis in adults. Nephrol. Dial.Transplant. 2003; 18 (Suppl. 6): vi45–vi51.


21. Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North AmericaNephrotic Syndrome Study Group. Kidney Int. 1999; 56(6): 2220–2226.


22. Goumenos D.S., Tsagalis G., El Nahas A.M. et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron. Clin. Pract. 2006; 104(2): c75–c82.


23. Braun N., Schmutzler F., Lange C. et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst. Rev. 2008;(3):CD003233.


24. Waldo F.B., Benfield M.R., Kohaut E.C. et al. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr. Nephrol. 1998; 12(5):397–400.


25. Lieberman K.V., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. 1996; 7(1): 56–63.


26. Mahmoud I., Basuni F., Sabry A. et al. Single-centre experience with cyclosporine in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol.Dial. Transplant. 2005; 20(4): 735–742.


27. Raafat R.H., Kalia A., Travis L.B., Diven S.C. High-dose oral cyclosporine therapy for recurrent focal segmental glomerulosclerosis in children. Am. J.Kidney Dis. 2004; 44(1): 50–56.


28. Drube J., Geerlings C., Taylor R. et al. Fifteen-year remission of a steroidresistant nephrotic syndrome sustained by cyclosporine A. Pediatr. Nephrol. 2007; 22(4): 600–602.


29. Yorgin P.D., Belson A., Higgins J., Alexander S.R. Pulse methylprednisolone, cyclosporine, and ace inhibitor therapy decreases proteinuria in two siblings with familial focal segmental glomerulosclerosis. Am. J. Kidney Dis. 2001; 37(6): E44.


30. Chishti A.S., Sorof J.M., Brewer E.D., Kale A.S. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am. J Kidney Dis. 2001; 38(4): 754–760.


31. Goumenos D.S. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert. Opin. Pharmacother. 2008; 9(10): 1695–1704.


32. De Santo N.G., Caposicasa G., Giordano C. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am. J. Nephrol. 1987; 7: 74–76.


33. Meyrier A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol. Dial. Transplant. 1992; 7 (Suppl.1): 80–84.


34. Rostocker G., Belghiti D., Ben Maadi A.D. et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63:335–341.


35. Сattran D.C., Greenwood C., Ritchie S. et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int. 1995; 47: 1130–1135.


36. Ambalavanan S., Fauvel J.P., Sibley R.K., Myers B.D. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc.Nephrol. 1996; 7(2): 290–298.


37. Goumenos D.S., Kalliakmani P., Tsakas S. et al. The remission of nephritic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin. Nephrol. 2004; 61(1): 17–24.


38. Alexopoulos E., Papagianni A., Tsamelashvili M. et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephritic syndrome. Nephrol. Dial. Transplant. 2006; 21(11): 3127–3132.


39. Goumenos D.S., Katopodis K.P., Passadakis P. et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am. J. Nephrol. 2007; 27(3): 226–231.


40. Pape L., Mengel M., Offner G., Ehrich J.H. Cyclosporin A-induced remission of primary membranous glomerulonephritis in a child. Nephrol. Dial. Transplant.2004; 19(12): 3207.


41. Eisterer W., Neyer U., Hilbe W. et al. Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia. Nephron. 1996; 72(3): 468–471.


42. Poncticelli C., Villa M. Does cyclosporin have a role in the treatment of membranous nephropathy? Nephrol. Dial. Transplant. 1999; 14: 23–25.


43. Тареева И.Е., Шилов Е.М., Краснова Т.Н. и др. Волчаночный нефрит в середине XX века и в начале XXI века. Тер. арх. 2001; 73(6): 5–10.


44. Ponticelli C., Glassock R.J., Moroni G. Induction and maintenance therapy in proliferative lupus nephritis. J. Nephrol. 2010; 23(01): 9–16.


45. Moroni G., Doria A., Mosca M. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 2006; 1(5): 925–932.


46. Ogawa H., Kameda H., Amano K., Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010; 19(2): 162–169.


47. Ogawa H., Kameda H., Nagasawa H. et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod. Rheumatol.2007;17(2): 92–97.


48. Baca V., Catalan T., Villasis-Keever M. et al. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus. 2006; 15(8): 490–495.


49. Hallegua D., Wallace D.J., Metzger A.L. et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus. 2000;9(4): 241–251.


50. Rihova Z., Vankova Z., Maixnerova D. et al. Treatment of lupus nephritis with cyclosporine – an outcome analysis. Kidney Blood Press. Res. 2007; 30(2): 124–128.


51. Lim B.J., Kim J.H., Hong S.W., Jeong H.J. Expression of fibrosis-associated molecules in IgA nephropathy treated with cyclosporine. Pediatr. Nephrol. 2009;24(3): 513–519.


52. Kiyomasu T., Shibata M., Kurosu H. et al. Cyclosporin A treatment for membranoproliferative glomerulonephritis type II. Nephron. 2002; 91(3):509–511.


53. Shin J.I., Park J.M., Shin Y.H. et al. Cyclosporin A therapy for severe Henoch-Schonlein nephritis with nephrotic syndrome. Pediatr. Nephrol. 2005; 20(8): 1093–1097.


54. Ronkainen J., Autio-Harmainen H., Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. Pediatr. Nephrol.2003; 18(11): 1138–1142.


Об авторах / Для корреспонденции


Козловская Л.В. – профессор кафедры терапии и профболезней МПФ ММА им. И.М. Сеченова, д.м.н.
Тел. 8(499) 248-59-59


Похожие статьи


Бионика Медиа